Ptg-100    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis8

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003452-75-NL
(EUCTR)
23/06/201704/01/2017A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000016670 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Protagonist Therapeutics, IncNULLNot Recruiting Female: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Poland;Belgium;Croatia;Netherlands;Germany;Latvia;Bosnia and Herzegovina
2EUCTR2016-003452-75-HR
(EUCTR)
11/05/201707/06/2017A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Poland;Belgium;Croatia;Germany;Latvia;Netherlands;Bosnia and Herzegovina
3EUCTR2016-003452-75-CZ
(EUCTR)
03/04/201719/12/2016A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2United States;Serbia;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Belgium;Poland;Croatia;Germany;Latvia;Netherlands;Bosnia and Herzegovina
4EUCTR2016-003452-75-LV
(EUCTR)
20/02/201723/11/2016A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Poland;Belgium;Croatia;Latvia;Germany;Netherlands;Bosnia and Herzegovina
5EUCTR2016-003452-75-HU
(EUCTR)
13/02/201701/12/2016A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Hungary;Czech Republic;Poland;Belgium;Croatia;Germany;Latvia;Netherlands;Bosnia and Herzegovina
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2016-003452-75-BE
(EUCTR)
13/02/201707/12/2016A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Poland;Belgium;Croatia;Germany;Latvia;Netherlands;Bosnia and Herzegovina
7EUCTR2016-003452-75-PL
(EUCTR)
09/02/201704/01/2017A study to examine the safety and effect of the study drug PTG-100 in patients with inflammation of the colonA PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS Moderate to Severe Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Product Name: PTG-100
Product Code: PTG-100
INN or Proposed INN: -
Other descriptive name: PN-10884A
Protagonist Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Serbia;United States;Slovenia;Greece;Ukraine;Russian Federation;United Kingdom;Czech Republic;Hungary;Poland;Belgium;Croatia;Netherlands;Germany;Latvia;Bosnia and Herzegovina
8NCT02895100
(ClinicalTrials.gov)
December 20164/9/2016Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisA Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative ColitisUlcerative ColitisDrug: PTG-100;Drug: PlaceboProtagonist Therapeutics, Inc.NULLTerminated18 Years80 YearsAll100Phase 2United States;Australia;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Germany;Hungary;Korea, Republic of;Latvia;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Ukraine